As Brexit votes loom, new drug regulatory pathway takes shape

While U.K. biopharma companies hold their breath hoping for any signs of a deal that might emerge from Wednesday’s debates in Parliament, a regulatory pathway for new medicines has begun to crystallize.

In the event of no deal, the “divorce” scheduled for April 12 will test the U.K. and Europe’s readiness. While U.K. companies would likely prefer any deal to no deal, they have been preparing for the latter for months...